Department of Pathology, University of Washington, Seattle, United States; Aging and Metabolism Program, Oklahoma Medical Research Foundation, Oklahoma City, United States
Huiliang Zhang
Department of Pathology, University of Washington, Seattle, United States
Mariya Sweetwyne
Department of Pathology, University of Washington, Seattle, United States
Jeremy Whitson
Department of Pathology, University of Washington, Seattle, United States
Ying Sonia Ting
Department of Genome Science, University of Washington, Seattle, United States
Nathan Basisty
Buck Institute for Research on Aging, Novato, United States
Lindsay K Pino
Department of Genome Science, University of Washington, Seattle, United States
Ellen Quarles
Department of Pathology, University of Washington, Seattle, United States
Ngoc-Han Nguyen
Department of Pathology, University of Washington, Seattle, United States
Matthew D Campbell
Department of Radiology, University of Washington, Seattle, United States
Tong Zhang
Biological Sciences Division, Pacific Northwest National Laboratory, Richland, United States
Matthew J Gaffrey
Biological Sciences Division, Pacific Northwest National Laboratory, Richland, United States
Gennifer Merrihew
Department of Genome Science, University of Washington, Seattle, United States
Lu Wang
Department of Environmental and Occupational Health Sciences, University of Washington, Seattle, United States
Yongping Yue
Department of Molecular Microbiology and Immunology, School of Medicine, University of Missouri, Columbia, United States
Dongsheng Duan
Department of Molecular Microbiology and Immunology, School of Medicine, University of Missouri, Columbia, United States
Diastolic dysfunction is a prominent feature of cardiac aging in both mice and humans. We show here that 8-week treatment of old mice with the mitochondrial targeted peptide SS-31 (elamipretide) can substantially reverse this deficit. SS-31 normalized the increase in proton leak and reduced mitochondrial ROS in cardiomyocytes from old mice, accompanied by reduced protein oxidation and a shift towards a more reduced protein thiol redox state in old hearts. Improved diastolic function was concordant with increased phosphorylation of cMyBP-C Ser282 but was independent of titin isoform shift. Late-life viral expression of mitochondrial-targeted catalase (mCAT) produced similar functional benefits in old mice and SS-31 did not improve cardiac function of old mCAT mice, implicating normalizing mitochondrial oxidative stress as an overlapping mechanism. These results demonstrate that pre-existing cardiac aging phenotypes can be reversed by targeting mitochondrial dysfunction and implicate mitochondrial energetics and redox signaling as therapeutic targets for cardiac aging.